Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy

This trial is testing a combination approach for men with prostate cancer that has spread to a small number of sites (up to 5 spots in the lymph nodes or bones). It combines a targeted radiation treatment called PSMA-directed therapy with a precise, high-dose radiation technique (stereotactic body radiotherapy, or SBRT) aimed at each of those spots. **You may be eligible if...** - You are a male aged 18 or older - You have been diagnosed with prostate cancer confirmed by biopsy - You previously had definitive treatment (surgery or radiation) for your primary prostate cancer - A special scan (PSMA PET/CT) shows 1 to 5 sites of spread in your lymph nodes or bones - Your blood counts and kidney function are within acceptable ranges - A radiation oncologist has determined you are suitable for the targeted radiation treatment - You are in good general health (able to perform daily activities with little to no restriction) **You may NOT be eligible if...** - You have had prior systemic treatment for metastatic prostate cancer (hormone therapy within the past 6 months also disqualifies you) - The cancer has spread to internal organs (lungs, liver, etc.) - You have spinal cord compression or signs of it - You have another active cancer being treated Talk to your doctor to see if this trial is right for you.